CA2289119C - Methods for treating inflammation and inflammatory diseases using padprt inhibitors - Google Patents

Methods for treating inflammation and inflammatory diseases using padprt inhibitors Download PDF

Info

Publication number
CA2289119C
CA2289119C CA2289119A CA2289119A CA2289119C CA 2289119 C CA2289119 C CA 2289119C CA 2289119 A CA2289119 A CA 2289119A CA 2289119 A CA2289119 A CA 2289119A CA 2289119 C CA2289119 C CA 2289119C
Authority
CA
Canada
Prior art keywords
lps
amino
compound
cells
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2289119A
Other languages
English (en)
French (fr)
Other versions
CA2289119A1 (en
Inventor
Ernest Kun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octamer Inc
Original Assignee
Octamer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/855,616 external-priority patent/US5908861A/en
Application filed by Octamer Inc filed Critical Octamer Inc
Publication of CA2289119A1 publication Critical patent/CA2289119A1/en
Application granted granted Critical
Publication of CA2289119C publication Critical patent/CA2289119C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
CA2289119A 1997-05-13 1998-05-13 Methods for treating inflammation and inflammatory diseases using padprt inhibitors Expired - Fee Related CA2289119C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/855,616 US5908861A (en) 1997-05-13 1997-05-13 Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US08/855,616 1997-05-13
US09/056,396 US6303629B1 (en) 1997-05-13 1998-04-06 Methods for treating inflammation, inflammatory diseases, arthritis and stroke using pADPRT inhibitors
US09/056,396 1998-04-06
PCT/US1998/010033 WO1998051308A1 (en) 1997-05-13 1998-05-13 METHODS FOR TREATING INFLAMMATION AND INFLAMMATORY DISEASES USING pADPRT INHIBITORS

Publications (2)

Publication Number Publication Date
CA2289119A1 CA2289119A1 (en) 1998-11-19
CA2289119C true CA2289119C (en) 2011-03-15

Family

ID=26735288

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2289119A Expired - Fee Related CA2289119C (en) 1997-05-13 1998-05-13 Methods for treating inflammation and inflammatory diseases using padprt inhibitors

Country Status (9)

Country Link
EP (1) EP1009404A4 (pt)
JP (1) JP4362638B2 (pt)
CN (1) CN1198614C (pt)
AU (2) AU7484798A (pt)
BR (1) BR9809115A (pt)
CA (1) CA2289119C (pt)
IL (1) IL132758A0 (pt)
NZ (1) NZ501650A (pt)
WO (2) WO1998051308A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4093448B2 (ja) 1999-01-11 2008-06-04 アグロン・ファーマシューティカルズ・インコーポレーテッド ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
ATE355278T1 (de) 2001-05-08 2006-03-15 Kudos Pharm Ltd Isochinolinon derivate als parp inhibitoren
ATE491703T1 (de) 2002-04-30 2011-01-15 Kudos Pharm Ltd Phthalazinonderivate
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
TWI389897B (zh) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
CA2612979A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. Parp modulators and treatment of cancer
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
WO2008030891A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
EP2059802A4 (en) * 2006-09-05 2010-09-08 Bipar Sciences Inc METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF
CN101641013B (zh) 2007-01-22 2014-07-30 Gtx公司 核受体结合剂
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
KR20100059950A (ko) 2007-09-14 2010-06-04 아스트라제네카 아베 프탈라지논 유도체
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
PT2346837E (pt) 2008-06-26 2015-04-02 Resverlogix Corp Métodos de preparação de derivados de quinazolinona
EP2346495B2 (en) 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
WO2010061908A1 (ja) 2008-11-28 2010-06-03 中外製薬株式会社 １－（２ｈ）－イソキノロン誘導体
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
BRPI1009315B8 (pt) 2009-03-18 2021-05-25 Resverlogix Corp composto anti-flamatórios e suas composições farmacêuticas
TR201818390T4 (tr) 2009-04-22 2019-01-21 Resverlogix Corp Yeni̇ anti̇-i̇nflamatuvar ajanlar
PL2773354T3 (pl) 2011-11-01 2019-12-31 Resverlogix Corp. Doustna formulacja o natychmiastowym uwalnianiu dla podstawowych chinazolinów
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
WO2018237327A1 (en) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. METHODS OF TREATING GLIOBLASTOMA
WO2019067991A1 (en) 2017-09-29 2019-04-04 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND USES THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503073A (ja) 1989-09-26 1993-05-27 オクタマー，インコーポレイテッド ウイルス性疾患の治療に有用な６―アミノ―１，２―ベンゾピロン
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5516941A (en) 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5473074A (en) 1991-10-22 1995-12-05 Octamer, Incorporated Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents-54
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5482975A (en) 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
DE4436127A1 (de) 1994-09-27 1996-03-28 Deutsches Rheumaforschungszent Verwendung von aromatischen Amiden und Säuren zur Behandlung von rheumatischen Erkrankungen
WO1996031206A2 (en) * 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
US10766598B2 (en) 2017-06-14 2020-09-08 The Boeing Company Wing-to-fuselage joints and aircraft including the same

Also Published As

Publication number Publication date
AU7492698A (en) 1998-12-08
AU7484798A (en) 1998-12-08
AU745790B2 (en) 2002-03-28
EP1009404A1 (en) 2000-06-21
IL132758A0 (en) 2001-03-19
BR9809115A (pt) 2002-01-02
WO1998051308A1 (en) 1998-11-19
NZ501650A (en) 2001-11-30
JP4362638B2 (ja) 2009-11-11
EP1009404A4 (en) 2009-07-01
CN1198614C (zh) 2005-04-27
CA2289119A1 (en) 1998-11-19
JP2002502367A (ja) 2002-01-22
WO1998051307A1 (en) 1998-11-19
CN1261278A (zh) 2000-07-26

Similar Documents

Publication Publication Date Title
CA2289119C (en) Methods for treating inflammation and inflammatory diseases using padprt inhibitors
US5908861A (en) Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
Kang et al. Inhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharide-stimulated macrophages
Jasiecka et al. Pharmacological characteristics of metamizole
Yan et al. Celastrol ameliorates Propionibacterium acnes/LPS-induced liver damage and MSU-induced gouty arthritis via inhibiting K63 deubiquitination of NLRP3
Chan et al. Adenosine A2A receptors play a role in the pathogenesis of hepatic cirrhosis
Kotanidou et al. Luteolin reduces lipopolysaccharide-induced lethal toxicity and expression of proinflammatory molecules in mice
Rawls et al. Effects of opioids, cannabinoids, and vanilloids on body temperature
Zhang et al. 6-Gingerol attenuates macrophages pyroptosis via the inhibition of MAPK signaling pathways and predicts a good prognosis in sepsis
Wang et al. A pure polysaccharide from Ephedra sinica treating on arthritis and inhibiting cytokines expression
BR112015015858B1 (pt) Uso de uma composição farmacêutica de solução sólida no tratamento de uma inflamação crônica
BRPI0616344A2 (pt) mÉtodo para o tratamento de dependÊncia quÍmica e comportamental
Chen et al. A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo
Smith et al. Prostaglandins and the anti‐inflammatory activities of aspirin and sodium salicylate
CA3101274A1 (en) Use of neutrophil elastase inhibitors in liver disease
Peng et al. Paeonol alleviates primary dysmenorrhea in mice via activating CB2R in the uterus
Dravid et al. Resolvin D1‐loaded nanoliposomes promote M2 macrophage polarization and are effective in the treatment of osteoarthritis
KR100701539B1 (ko) 멜라가트란의 신규 용도
Tao et al. Exploring the mechanism through which Phyllanthus emblica L. Extract exerts protective effects against acute gouty arthritis: a network pharmacology study and experimental validation
Helgason et al. DNA fragmentation induced by cytotoxic T lymphocytes can result in target cell death
Toth et al. Tumorigenic effect of 4-methylphenylhydrazine hydrochloride in Swiss mice
Rowe et al. The effect of fluoxetine on warfarin metabolism in the rat and man
WO2005123053A2 (en) Use of cb2 receptors agonists for the treatment of huntington’s disease
Alexandre-Moreira et al. LASSBio-468: a new achiral thalidomide analogue which modulates TNF-α and NO production and inhibits endotoxic shock and arthritis in an animal model
MXPA99010417A (en) METHODS FOR TREATING INFLAMMATION AND INFLAMMATORY DISEASES USING pADPRT INHIBITORS

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170515